Gilead Sciences

Vertex Pharmaceuticals

Amgen

Regeneron Pharmaceuticals

IQVIA Hlds

Alnylam Pharmaceuticals

Mettler-Toledo

Biogen

Illumina

Waters

iShares Nasdaq Biotechnology ETF

IBB tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges.

iShares Emerging Markets Dividend ETF

Home Depot

Walmart

Financial Select Sector SPDR Fund

Technology Select Sector SPDR Fund

Consumer Discretionary Select Sector SPDR Fund

Core inflation for the month of October marked its slowest pace in over two years. Several retailers are also of the view that the worst of inflation is over.

"Worst of U.S. Inflation Over"? ETF Areas Likely to Gain

ARK Genomic Revolution Multi-Sector ETF

SPDR S&P Biotech ETF

The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.

How to Find the Best Biotech ETFs

SPDR S&P Regional Banking ETF

VanEck Vectors Semiconductor ETF

Most of you know our Big View product, since I often talk about our risk gauges. In fact, I can report to you that our risk gauges show 3 out of the 5 with risk off.

Stock Market ETFs to Watch: Semiconductors (SMH), Biotechnology (IBB), Regional Banks (KRE)

VanEck Vectors Biotech ETF

Invesco Nasdaq Biotechnology ETF

Invesco Dynamic Pharmaceuticals ETF

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

Time for Gilead Sciences-Heavy ETFs?

abrdn Healthcare Investors 

Direxion Daily S&P Biotech Bull 3X Shares

Lonza Group AG

Merck

Navistar

Omega Healthcare Investors

Pfizer

Royalty Pharma

abrdn World Healthcare Fund 

Wuxi Biologics Cayman Inc

Health Care Select Sector SPDR Fund

The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. Investors can consider diversified biotech indexes or healthcare-focused ETFs for exposure to the biopharma sector.

Biopharma Bounce-Back: From Policy Pains To Profitable Plains

The biotechnology sector has disappointed overall; we think there are better ways to get exposure to the healthcare sector. iShares Biotechnology ETF has underperformed relative to Health Care Select Sector SPDR® Fund ETF. Investing in a broader healthcare ETF like XLV may offer more diversification, less volatility, and better long-term growth prospects.

IBB: The Illness Of Idiosyncratic Risk

Biotechnology has traded basically sideways since the start of 2023. In the face of higher rates, stronger dollar, inflation, FDA approvals and busts, and an emerging winter season, the ETF IBB has a serenity to it that appears drug-induced if you will.

Sector ETF Spotlight: $IBB Biotechnology on Drugs

Exelixis

The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.

3 Strong Biotech Performers To Watch As Sector Nears Breakout

BioNTech SE

United Therapeutics

The events of the last few years have made biotech investing look easier than it is. But, investing in biotech is not for the faint of heart.

The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023

ARK Innovation ETF

Vanguard S&P 500 ETF

ETFs can be an easy, powerful way to diversify your stock holdings. While there are dozens of options, Ark Innovation, iShares Biotechnology, and Vanguard 500 Index Fund are three ETFs that should shine in 2023 and beyond.

3 Top ETFs to Buy Right Now

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

Is Now the Right Time to Embrace Biotech ETFs?

Global X Telemedicine & Digital Health ETF

iShares U.S. Medical Devices ETF

Let's explore the burgeoning world of FemTech, a sector dedicated to women's health, and discover why it's a lucrative investment opportunity.

This Often-Ignored FemTech Industry Looks Hot: ETFs to Play

Biotech stocks have been largely out of relative favor in 2023. Amid possible market mean reversion and seasonal tailwinds, IBB's low P/E is a positive attribute. But poor absolute price action and relative performance weakness lead me to reiterate my hold rating.

Biotech Continues To Struggle Against The Broad Market, IBB Remains A Hold

The iShares Biotechnology ETF NASDAQ: IBB has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible shifts within the biotechnology sector.

Is the Biotech Industry (IBB) Poised For A Major Breakout?

SPDR Dow Jones Industrial Average ETF

The US private domestic sector balance increased by $130bn in May 2023, a positive result driven by a $246bn injection of funds from the federal government. Bank credit creation retraction continued for the fifth consecutive month, signaling a potential economic downturn.

The Private Domestic Sector Prints A $130B Surplus In May Pointing To Better Markets In June

ACADIA Pharma

Agios Pharmaceuticals

BioMarin Pharmaceutical

CareDx

Exact Sciences

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Ionis Pharma

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Seagen

Teladoc

TG Therapeutics

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Global X Robotics & Artificial Intelligence ETF

First Trust Dorsey Wright Focus 5 ETF

iShares Robotics & Artificial Intelligence Multisector ETF

JPMorgan US Momentum Factor ETF

Direxion NASDAQ-100 Equal Weighted Index Shares

iShares MSCI USA Quality Factor ETF

Alpha Architec U.S. Quantitative Value ETF 

ROBO Global Robotics and Automation ETF

Invesco S&P 500 Pure Value ETF

ALPS Sector Dividend Dogs ETF

Invesco S&P 500 Quality ETF

Communication Services Select Sector SPDR Fund

This week, the VettaFi Voices gather around the water cooler and talk smart beta and equal weight ETFs.

VettaFi Voices On: Smart Beta and Equal-Weight ETFs

The Biotech space has not caught much of a tailwind from lower interest rates lately. After a stellar relative return in the second half of 2022, the trend has turned in favor of the bears.

Biotech's Bearish Turn In 2023, But Eyeing Bullish Seasonal Trends In IBB

IBB invests in biotechnology stocks predominantly in the United States. The healthcare sector is renowned for its relative stability during market fluctuations compared to that of more procyclical alternatives in sectors like financials and technology.

IBB: Biotechnology Securities Might Be Getting More Attractive As Recession Fears Loom

Simplify Health Care ETF

Sanofi

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Virtus LifeSci Biotech Clinical Trials ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

SPDR S&P Pharmaceuticals ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Loncar Cancer Immunotherapy ETF

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

ALPS Medical Breakthroughs ETF

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Rising interest rates taking steam from rally that powered in IBB and XBI. 

The Recent Bullish Trend in IBB, XBI Looks Shaky

Horizon Pharma

The latest earnings from some of the big biotech players came in at mixed this reporting season.

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

News for iShares Nasdaq Biotechnology ETF ETF (IBB)